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ABSTRACT
Background: The use of endosseous dental implants has become common practice for the rehabilitation of edentulous
patients, and a two-implant overdenture has been recommended as the standard of care. The use of small-diameter
implants may extend treatment options and reduce the necessity for bone augmentation. However, the mechanical strength
of titanium is limited, so titanium alloys with greater tensile and fatigue strength may be preferable.
Purpose: This randomized, controlled, double-blind, multicenter study investigated in a split-mouth model whether
small-diameter implants made from Titanium-13Zirconium alloy (TiZr, Roxolid™) perform at least as well as Titanium
Grade IV implants.
Methods and Materials: Patients with an edentulous mandible received one TiZr and one Ti Grade IV small-diameter bone
level implant (3.3 mm, SLActive®) in the interforaminal region. The site distribution was randomized and double-blinded.
Outcome measures included change in radiological peri-implant bone level from surgery to 12 months post-insertion
(primary), implant survival, success, soft tissue conditions, and safety (secondary).
Results: Of 91 treated patients, 87 were available for the 12-month follow-up. Peri-implant bone level change
(-0.3 1 0.5 mm vs -0.3 1 0.6 mm), plaque, and sulcus bleeding indices were not significantly different between TiZr and Ti
Grade IV implants. Implant survival rates were 98.9 percent and 97.8 percent, success rates were 96.6 percent and 94.4
percent, respectively. Nineteen minor and no serious adverse events were related to the study devices.
Conclusion: This study confirms that TiZr small-diameter bone level implants provide at least the same outcomes after 12
months as Ti Grade IV bone level implants. The improved mechanical properties of TiZr implants may extend implant
therapy to more challenging clinical situations.
KEY WORDS: alloy, bone level implant, double-blind, edentulous mandible, Locator, RCT, Titanium, Zirconium
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INTRODUCTION
Partial or full edentulism impairs masticatory function
significantly and is a major oral health concern in a large
part of the adult population.1 Traditional treatments
comprising prostheses are often inadequate in restoring
full masticatory function and can negatively affect nutri-
tion, physical appearance, and self-esteem2. These prob-
lems generally worsen with age as additional teeth are
lost and alveolar bone resorption further renders the
stability of conventional dentures difficult.3 To over-
come these limitations and facilitate masticatory func-
tion, the attachment of dentures to endosseous dental
implants has become common clinical practice.1,4,5
Demographic data indicate increasing proportions
of the elderly in the population and augmented indi-
vidual life expectancies. Despite a trend to lose natural
teeth later in life, edentulism remains a relevant oral
health condition in elderly adults.6,7 A recent Swiss
survey revealed that 37 percent of the population aged 85
years and over were edentulous.8 Tooth loss implies sig-
nificant functional and structural changes which can
only partly be restored by means of conventional com-
plete dentures. The insertion of two interforaminal
implants to support and retain a lower denture has
proven to be an efficient, cost-effective, and moderately
invasive treatment option.9 Implant-supported overden-
tures allow for a significantly better chewing efficiency
and decrease the bone loss in the implant-supported
areas.10,11 In addition to these functional and structural
advantages, they can improve the edentulous patient’s
self-confidence, well-being, and social interactions and
thus contribute to a better quality of life.12 A two-implant
overdenture was therefore recommended as first choice
of treatment for the edentulous mandible.13,14
The introduction of small-diameter (23.5 mm)
implants has improved treatment options for challeng-
ing clinical indications such as placing implants in
single-tooth gaps or edentulous ridges with limited
width. The material of small-diameter implants must
fulfill high demands on mechanical stability to avoid
overload and implant fracture. Titanium is widely
used for dental implants because of its corrosion resis-
tance and biocompatibility superior to Titanium-
Aluminium-Vanadium alloys.15 In rats, implants from
pure Titanium did not cause systemic toxicity or
decrease immune activity, body weight, or the weight of
any individual organ. Titanium alloys containing Zir-
conium show better tensile and fatigue strength than
pure Titanium.16 A Titanium-Zirconium [Titanium-
13Zirconium (TiZr)] alloy (Roxolid™, Institut Strau-
mann AG, Basel, Switzerland) with the SLActive®
(Institut Straumann AG, Basel, Switzerland) surface has
been developed in order to increase the fatigue strength
for small-diameter implants, but with comparable
osseointegration as for Titanium Grade IV implants (TI
Grade IV). The biocompatibility of TiZr alloys has been
shown in preclinical in vitro and in vivo models. In
vitro, limb bud cells grown on TiZr showed better
chondrogenic differentiation compared with cells
grown on pure Titanium.17 In rats, subcutaneously
implanted TiZr alloys were surrounded by less inflam-
matory cells and had a lower tissue response score com-
pared with implants from pure Titanium.15 Zirconium
as implant material also increased the amount of bone-
implant contact compared with pure Titanium,18 and
recently, the quality of the osseointegration of Roxolid
implants with the SLActive surface has been proven to
be comparable to that of titanium in minipigs.19
The aim of this clinical trial was to test the hypoth-
esis that small-diameter (3.3 mm) bone level implants
made from TiZr achieve at least the same outcome in
terms of peri-implant bone level change, physical stabil-
ity, and safety as implants made from Ti Grade IV after
6 and 12 months follow-up in patients with edentulous
mandibles restored with removable overdentures.
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MATERIALS AND METHODS
Study Sites and Patients
The study was designed as a prospective randomized,
controlled, double-blind, split-mouth, non-inferiority,
multicenter clinical trial conducted at eight sites in five
countries (Germany, Italy, Belgium, the Netherlands,
and Switzerland). Male and female patients were
recruited according to the inclusion and exclusion crite-
ria detailed in Table 1.
This clinical study was carried out in accordance
with the rules of good clinical practice (according to ISO
TABLE 1 Inclusion and Exclusion Criteria for Participation in the Study
Inclusion criteria
• Voluntary informed consent
• Age 318 years
• Edentulous mandible at the time of surgery
• Last tooth extracted >8 weeks before date of first stage surgery
• Edentulous opposing dentition with a denture (implant-borne or conventional) or natural or restored teeth
• Adequate bone height 39 mm above vital structures in the intraforaminal region and sufficient bone width to allow
placement of 3.3 mm implants without concurrent bone augmentation
• Commitment to participate in the study for 3 years of follow-up examinations
Exclusion criteria (systemic)
• Medical conditions requiring prolonged use of steroids
• Severe hemophilia
• Bisphosphonate medication
• History of leukocyte dysfunction and deficiencies
• History of head and neck radiation or chemotherapy
• History of renal failure
• History of uncontrolled endocrine disorders
• Physical handicaps interfering with ability to perform adequate oral hygiene
• Use of any investigational drug or device within 30 days prior to implant surgery
• Alcoholism or drug abuse
• HIV infection
• Smoking >10 cigarettes or cigar equivalents per day or chewing tobacco >10 cigarette equivalents per day
• Absence of adequate birth control in females
• Conditions or circumstances which would prevent completion of study participation or interfere with analysis of study results
(eg, non-compliance)
Exclusion criteria (local)
• Local inflammation, including untreated periodontitis
• Mucosal diseases such as erosive lichen planus
• History of local irradiation therapy
• Presence of osseous lesions
• Unhealed extraction sites
• History of bone reconstruction and bone grafting techniques at site of intended implant placement
• Severe bruxing or clenching habits
• Persistent intraoral infection
• Patients with inadequate oral hygiene or unmotivated for adequate home care
Exclusion criteria (secondary)
• Need for GBR treatment at implant surgery
• Insufficient bone or any other bone abnormality that contraindicated placement
• Inappropriate treatment according to Study Protocol
• Lack of primary implant stability at time of abutment connection (ie, spinning implant at 35 Ncm torque or laterally moving
implant)
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14155) and approved by the Ethics Committees of all
study sites. All patients provided written informed
consent.
Study Design
Patients received two Straumann Bone Level Implants
(Institut Straumann AG, Basel, Switzerland) of 3.3 mm
diameter with the SLActive surface. One of the two
implants was fabricated from TiZr alloy and the other
one from Ti Grade IV. Except for the material, both
devices were identical and the sterile glass-tube contain-
ers were marked A or B. Blinding keys were kept cen-
trally at the sponsor. The first implant was randomly
allocated to either the right or left interforaminal region
of the edentulous mandible, the other one was placed in
the contralateral side. Randomization was performed
using sealed envelopes which were opened after bone
exposure during surgery. Clinical examinations were
performed after 6 months, but the study was unblinded
only after 12 months post-surgery.
Primary outcome measure was the change of peri-
implant bone level from surgery to 12 months follow-
up. Secondary outcomes were soft tissue conditions
(plaque index, sulcus bleeding index) after 6 and 12
months, as well as survival, success, and safety of the
implants after 12 months. Calibration of the clinical
examination was performed to ensure consistent evalu-
ation of the implant sites by all investigators. After
unblinding at 12 months post-surgery, follow-up visits
at 24 and 36 months will be performed.
Surgical Procedure
Surgery was performed under local anesthesia following
a standardized protocol. The drilling sequence was fin-
ished with a crestal drill for all implants. The implant
was placed in the recipient site by means of an insertion
device and a hand ratchet or motor drive. Implants of 8,
10, 12, and 14 mm length were available. Insertion depth
was of bone level, but exposure of one thread was
allowed if clinically adequate. Healing abutments were
inserted for transmucosal healing. Sutures were
removed 1–2 weeks after first-stage surgery. The healing
abutments were replaced by Locator abutments (Zest
Anchors LLC, Escondido, CA, USA) 6–8 weeks after
surgery. The removable dentures were relined for the
incorporation of the female Locator parts. No metal
framework was placed.
Peri-Implant Bone Level
Standardized panoramic radiographs were taken at
baseline and 12 months post-surgery, and were evalu-
ated at the University of Bern by an independent inves-
tigator (R.P.) who was blinded to the implant material.
Digital panoramic images were analyzed using NIH
ImageJ 1.33 open software. Film-based panoramic
images were digitized using a video camera, light box,
and the image analysis program as described in Brägger
(1998)20 and Brägger (2004).21 In both assessments, the
known implant length was used as a reference to trans-
form the linear measurements into millimeters. Refer-
ence line for bone level evaluation was the implant
chamfer that is located 0.2 mm above the implant shoul-
der. Mesial and distal bone changes in this region were
considered as remodeling. Peri-implant bone change
was defined as difference in bone height with reference
to the implant shoulder (below this line, the implant
exhibits a SLActive surface; Figure 1).
Implant Survival and Success
Implant survival was defined as the implant being still in
place at the 12-month follow-up. Implant success
was defined according to Buser and colleagues22 as
Figure 1 Schematic drawing of x-ray measurement of the
implant and the surrounding bone (1 = Chamfer to first mesial
implant-to-bone contact; 2 = Chamfer to first distal implant to
bone contact; 3 = Length of implant).
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possibility for restoration and absence of: a) persistent
pain, foreign body sensation and/or dysesthesia; b)
recurrent peri-implant infection with suppuration; c)
implant mobility; and d) continuous radiolucency
around the implant.
Success criteria for the prosthesis are defined as
being stable and in good function and absence of: a)
abutment mobility; b) corrective measurements to
the prosthesis; and c) repairs to either prosthesis or
abutment.
Soft Tissue Assessment
Soft tissue status was evaluated by assessment of modi-
fied plaque index (PI) and modified sulcus bleeding
index (SBI; bleeding on probing). PI and SBI at buccal,
palatal distal, and mesial sites were measured on each
implant according to the criteria described by Mombelli
and colleagues.23
Safety
Safety of the implants was evaluated by recording all
reported complications, adverse events (AEs), and
serious adverse events (SAEs). Each AE and SAE was
assessed for severity and its potential relationship to the
implant device.
Statistical Analyses
Results with parametric distribution are presented as
mean values (1 standard deviation). Comparisons
between the study groups were performed by a paired
t-test, Wilcoxon-signed rank test, and McNemar’s test as
appropriate. The confirmatory non-inferiority test was
performed at a one-sided 97.5 percent confidence inter-
val (CI), whereas a difference of 0.1 mm in the change of
peri-implant bone level was considered as clinically
acceptable. Sample size was calculated for a significance
level of 0.05 with a power of 80 percent.
The safety population comprises all randomized
patients who received the test and control implant. The
Intent to Treat (ITT) population comprises all random-
ized patients who received implants and underwent at
least one efficacy assessment. The per protocol (PP)
population comprises all randomized patients who
received the implants without major protocol violations
and whose implants reached primary stability. Primary
and secondary efficacy parameters were analyzed for the
ITT and the PP population. In order to avoid unneces-
sary re-exposition of patients to radiation, missing
radiographs at the 12-months visit were substituted with
radiographs at the 6-months visit if available. This
might underestimate the bone loss to a minimal extent,
but is a systematical bias which is ruled out by the split-
mouth design and the pair-wise testing. All other
missing efficacy parameters were handled as missing.
Unavailable data in the safety population were treated as
missing, except for severity and relationship of AEs that




Patient recruitment began in October 2007 and the last
12-month follow-up was performed in September 2009.
The study screened 92 patients; of these, 91 patients
received implants. No efficacy data were obtained from
one patient, and treatment allocation was unknown in
another patient; therefore, these patients were not
included in the patient set analyzed (n = 89, ITT popu-
lation, Figure 2). Furthermore, one patient withdrew
consent after implant loss, and another patient died –
both before the 12-month visit.
The mean age of the ITT population was 65.8 1 8.35
years (range 49–86 years). There were no relevant differ-
ences in the physical appearance, tissue quality, and
Figure 2 Patient flow. One screened patient had two major
protocol violations (primary efficacy data were not assessed and
surgery was not performed according to protocol) and was
therefore not eligible for treatment.
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surface morphology of the soft tissue between the
patients in the two implant groups and from time of
surgery to abutment connection. Fair or poor oral
hygiene was reported in 9 percent and 13.5 percent of
implants in the TiZr and Ti Grade IV group, respectively.
Primary Outcome Measure
Mean peri-implant bone level change 12 months post-
surgery was not significantly different between the TiZr
group (-0.34 1 0.54 mm) and the Ti Grade IV group
(-0.31 1 0.56 mm). The majority of implant sites (>70
percent in each implant group) showed minimal change
in bone level (Figure 3). Of note, most of the change in
bone level occurred within the first 6 months
(-0.23 1 0.35 mm vs -0.23 1 0.40 mm). The one-sided
97.5 percent CI of the difference between the implant
groups at 12-month follow-up (paired t-test) was [-•,
0.087]. As the non-inferiority margin of 0.1 is not part of
this confidence interval, the non-inferiority of TiZr
compared with Ti Grade IV was statistically proven. The
non-inferiority of TiZr was confirmed by analysis of the
PP population (97.5 percent CI for treatment difference
[-•, 0.096]).
Secondary Outcome Measures
Three implants were lost during the study: one in the
TiZr group and two in the Ti Grade IV group. This
corresponds to survival rates of 98.9 percent (TiZr) and
97.8 percent (Ti Grade IV). All implant losses occurred
before locator abutment connection. One patient pre-
sented with recurrent peri-implant infection, so that
neither of his implants met the success criteria at 12
months. Considering missing data as failure, the
12-month success rates were 96.6 percent in the TiZr
and 94.4 percent in the Ti Grade IV group. When
excluding patients with missing data, the 12-month
success rates were 98.9 percent and 98.8 percent in the
TiZr and Ti Grade IV group, respectively.
Modified PI and modified SBI scores, as illustrated
in Table 2, are based on the highest measures recorded at
the mesial, buccal, distal, and oral sites. There was no
significant difference in PI and SBI scores between the
investigated implant types, neither at 6 nor at 12
months.
Safety
Out of the 91 patients of the safety population, a total
of 26 patients (28.6 percent) experienced 37 AEs during
the course of the study, of which 19 were judged to be
related to the study device; most common were minor
inflammation at the implant site, tactile implant mobil-
ity, loosening of a prosthetic component, and minor
discomfort due to the surgical procedure. Seven
Figure 3 Peri-implant bone change at 12 months post-surgery
(n = 78 Ti Grade IV implants, n = 82 TiZr implants). In the
majority of implant sites, minimal change in bone level
(<0.5 mm) was observed.
TABLE 2 Modified Plaque Index (PI) and Modified Sulcus Bleeding Index
(SBI) according to Mombelli and Colleagues (1987)23 at 12-Month
Follow-Up (n = 89; ITT)
Score
PI SBI
TiZr n (%) Ti Grade IV n (%) TiZr n (%) Ti Grade IV n (%)
Missing 2 (2.3) 4 (4.5) 2 (2.3) 4 (4.5)
Score 0* 49 (55.1) 44 (49.4) 52 (58.4) 49 (55.1)
Score 1 14 (15.7) 12 (13.5) 22 (24.7) 23 (25.8)
Score 2 18 (20.2) 26 (29.2) 12 (13.5) 13 (14.6)
Score 3 6 (6.7) 3 (3.4) 1 (1.1) 0 (0.0)
*p = .3617 for PI and p = .9933 for SBI
TiZr, Titanium-13Zirconium.
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patients (7.7 percent) experienced a SAE, none of
which were related to the study device. One patient
presented with an osteomyelitis related to the surgical
procedure.
DISCUSSION
In patients with edentulous mandibles, small-diameter
bone level implants from a TiZr alloy (Roxolid) achieved
similar outcomes after 12 months as implants made
from Ti Grade IV (both with SLActive surface modifi-
cation). Based on the primary outcome measure of
change in peri-implant bone level, TiZr was non-
inferior to Ti Grade IV, and the similarity of results in
the PP and ITT populations supports the robustness of
the results.
Small-diameter implants are usually recommended
for single-tooth gaps with limited interdental space as
well as narrow edentulous ridges.24 The increasing clini-
cal success of these implants might reduce the necessity
of invasive bone augmentation procedures, which would
enhance patient acceptance of implant interventions
and reduce the treatment cost. Implants with small
diameters must withstand a high mechanical load to
avoid implant fracture. However, the mechanical
strength of pure Titanium is limited15,16; therefore, new
materials for implant production with more favorable
mechanical properties have been developed. Titanium
alloys containing Zirconium show better tensile and
fatigue strength than pure Titanium.16 Furthermore, the
TiZr alloy allows for the same SLA® and SLActive
surface modification as Ti Grade IV. In this study,
implants with the SLActive surface were used as this
surface modification is associated with significantly
improved bone-to-implant contact and faster healing
compared with the SLA surface.25
In the present study, no implant fractures and no
clinical differences regarding the efficacy of the TiZr
alloy compared with Ti Grade IV were observed.
Overall, the survival rate of both implant types in this
study compared well with those of small-diameter
implants in different settings.24,26–29 A prospective evalu-
ation of 298 two-part, 3.3 mm International Team for
Implantology (ITI) Ti Grade IV implants revealed a
cumulative 5-year survival rate of 98.7 percent, with two
implant body fractures after 2 and 6 years, respectively.24
In the same study, it was concluded that fatigue fracture
may occur after a long period of function. In another
longitudinal study comparing the clinical outcome of
122 small diameter (3.3 mm) with 208 standard diam-
eter (4.1 mm) ITI implants over a 7-year period, cumu-
lative survival rates for the narrow-diameter implants
were 98.1 percent (maxilla) and 96.9 percent (mandible)
and cumulative success rates were 96.1 percent and 92.0
percent.28 The data presented here do not yet allow a
final judgment on long-term success and implant frac-
ture. At the 12-month follow-up, two of the 3.3 mm
bone level implants (one Ti, one TiZr) in a single patient
were not successful because of recurrent peri-implant
infection; plaque index in this case suggests a poor oral
hygiene as a possible reason.
Implants with an even smaller diameter than in the
present study have been successfully used in clinical
studies for the edentulous lower jaw. In a prospective
study on two interforaminal two-piece mini-implants
with 2.5 mm diameter in 67 edentulous patients, a 95.5
percent survival rate30 after a mean follow-up of 6 years
was found. A multicenter study on one-piece Mini-
Dental-Implants (MDI 2.9 mm diameter) (n = 1,029)
revealed failure rates between 6 and 31 percent in the
same type of patients with four interforaminal
implants.31 This difference in success rates is not further
explained in the mentioned study.
Peri-implant bone loss after 6 and 12 months was
similar in both implant groups and was found to be
lower than observed by Romeo and colleagues in their
longitudinal study of narrow diameter implants.28
Zarone and colleagues observed 0.6 mm bone loss 6
months after loading of narrow neck ITI implants as
maxillary lateral incisor replacement.29 In the present
study, most of the bone loss occurred during the first 6
months after surgery. Similar observations were made
for Astra Tech and Brånemark implants, suggesting a
steady state in marginal bone levels 5 months after
fixture placement.32
One important concern regarding the safety of
implant alloys refers to their biocompatibility and the
possible release of metal ions. Zirconium has similar
properties to Titanium; both present neither local nor
systemic toxicity. In a rat model, TiZr alloy with 50 atom
percent Zirconium implanted for 8 months showed
better biocompatibility than pure Titanium. It showed
a lower tissue inflammatory and no sensitization
response.15 Accordingly, the soft tissue assessment
showed no negative impact of the TiZr implants com-
pared with Ti Grade IV. In the present study, no hyper-
sensitivity reactions or other adverse events suggesting
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metal ion intoxication were clinically observed in the
gingival tissues.
Patient parameters are an inherent source of vari-
ability in any clinical study. The split-mouth design of
the present study precludes patient-related bias, but
independence of data might be compromised by cross-
infection.33 Such model has already been successfully
used in implant dentistry comparing different sys-
tems.34–37 A “carry cross effect,” which is reported for
periodontal trials38 can be existent by cross infection or
due to the mechanical connection of the two implants by
the restoration. This potential decrease in validity is care-
fully weighed by the authors against the gain in precision.
CONCLUSION
This prospective randomized, controlled, double-blind
clinical trial in patients with edentulous mandibles con-
firms the hypothesis that the TiZr alloy, Roxolid, per-
forms at least as well as Titanium Grade IV when used as
material for 3.3 mm bone level implants with SLActive
surface. The improved mechanical properties of TiZr
implants may extend implant therapy to more challeng-
ing clinical situations, but further clinical studies on the
long-term performance of implants from this new TiZr
material are required.
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